Anti-Human VEGFR2/KDR/Flk-1 Reference Antibody (IMC-1C11, RUO) (HW338013)

Name: Anti-Human VEGFR2/KDR/Flk-1 Reference Antibody (IMC-1C11, RUO)
Brand: abinScience
SKU: HW338013
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

HW338013

Description

Anti-Human CD309/KDR/VEGFR-2 (IMC-1C11) (HW338013) is a research-grade recombinant antibody targeting CD309. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Reactivité des espèces

Human

Applications

ELISA, Bioactivity: FCM, Functional assay, Research in vivo

Espèce hôte

Chimeric

Clonalité

Monoclonal

Isotype

IgG1

ID de clone

IMC-1C11

Cible

CD309, EC:2.7.10.1, FLK-1, FLK1, Fetal liver kinase 1, KDR, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, VEGFR-2, VEGFR2, Vascular endothelial growth factor receptor 2

Niveau d'endotoxines

< 10 EU/mg

Pureté

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Numéro d'accès

P35968

Forme

Liquid

Tampon de stockage

0.01M PBS pH 7.4.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
ELISA	1:2000-1:20000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Contexte

Vascular endothelial growth factor receptor 2 (CD309/VEGFR-2) is a ~151 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. CD309 is the therapeutic target of ramucirumab (Cyramza).

Note

For research use only. Not suitable for clinical or therapeutic use.

Images